Metabotropic glutamate receptors

From the workbench to the bedside

F. Nicoletti, J. Bockaert, G. L. Collingridge, P. J. Conn, F. Ferraguti, D. D. Schoepp, J. T. Wroblewski, J. P. Pin

Research output: Contribution to journalArticle

358 Citations (Scopus)

Abstract

Metabotropic glutamate (mGlu) receptors were discovered in the mid 1980s and originally described as glutamate receptors coupled to polyphosphoinositide hydrolysis. Almost 6500 articles have been published since then, and subtype-selective mGlu receptor ligands are now under clinical development for the treatment of a variety of disorders such as Fragile-X syndrome, schizophrenia, Parkinson's disease and l-DOPA-induced dyskinesias, generalized anxiety disorder, chronic pain, and gastroesophageal reflux disorder. Prof. Erminio Costa was linked to the early times of the mGlu receptor history, when a few research groups challenged the general belief that glutamate could only activate ionotropic receptors and all metabolic responses to glutamate were secondary to calcium entry. This review moves from those nostalgic times to the most recent advances in the physiology and pharmacology of mGlu receptors, and highlights the role of individual mGlu receptor subtypes in the pathophysiology of human disorders. This article is part of a Special Issue entitled 'Trends in Neuropharmacology: In Memory of Erminio Costa'.

Original languageEnglish
Pages (from-to)1017-1041
Number of pages25
JournalNeuropharmacology
Volume60
Issue number7-8
DOIs
Publication statusPublished - Jun 2011

Fingerprint

Metabotropic Glutamate Receptors
Glutamic Acid
Neuropharmacology
Phosphatidylinositol Phosphates
Fragile X Syndrome
Dyskinesias
Glutamate Receptors
Gastroesophageal Reflux
Anxiety Disorders
Chronic Pain
Parkinson Disease
Schizophrenia
Hydrolysis
History
Pharmacology
Ligands
Calcium
Research

Keywords

  • Clinical studies
  • Metabotropic glutamate receptors
  • mGlu receptor ligands
  • Receptor structure

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Nicoletti, F., Bockaert, J., Collingridge, G. L., Conn, P. J., Ferraguti, F., Schoepp, D. D., ... Pin, J. P. (2011). Metabotropic glutamate receptors: From the workbench to the bedside. Neuropharmacology, 60(7-8), 1017-1041. https://doi.org/10.1016/j.neuropharm.2010.10.022

Metabotropic glutamate receptors : From the workbench to the bedside. / Nicoletti, F.; Bockaert, J.; Collingridge, G. L.; Conn, P. J.; Ferraguti, F.; Schoepp, D. D.; Wroblewski, J. T.; Pin, J. P.

In: Neuropharmacology, Vol. 60, No. 7-8, 06.2011, p. 1017-1041.

Research output: Contribution to journalArticle

Nicoletti, F, Bockaert, J, Collingridge, GL, Conn, PJ, Ferraguti, F, Schoepp, DD, Wroblewski, JT & Pin, JP 2011, 'Metabotropic glutamate receptors: From the workbench to the bedside', Neuropharmacology, vol. 60, no. 7-8, pp. 1017-1041. https://doi.org/10.1016/j.neuropharm.2010.10.022
Nicoletti F, Bockaert J, Collingridge GL, Conn PJ, Ferraguti F, Schoepp DD et al. Metabotropic glutamate receptors: From the workbench to the bedside. Neuropharmacology. 2011 Jun;60(7-8):1017-1041. https://doi.org/10.1016/j.neuropharm.2010.10.022
Nicoletti, F. ; Bockaert, J. ; Collingridge, G. L. ; Conn, P. J. ; Ferraguti, F. ; Schoepp, D. D. ; Wroblewski, J. T. ; Pin, J. P. / Metabotropic glutamate receptors : From the workbench to the bedside. In: Neuropharmacology. 2011 ; Vol. 60, No. 7-8. pp. 1017-1041.
@article{c1452fa610ac40a29a0ea1a24780f59b,
title = "Metabotropic glutamate receptors: From the workbench to the bedside",
abstract = "Metabotropic glutamate (mGlu) receptors were discovered in the mid 1980s and originally described as glutamate receptors coupled to polyphosphoinositide hydrolysis. Almost 6500 articles have been published since then, and subtype-selective mGlu receptor ligands are now under clinical development for the treatment of a variety of disorders such as Fragile-X syndrome, schizophrenia, Parkinson's disease and l-DOPA-induced dyskinesias, generalized anxiety disorder, chronic pain, and gastroesophageal reflux disorder. Prof. Erminio Costa was linked to the early times of the mGlu receptor history, when a few research groups challenged the general belief that glutamate could only activate ionotropic receptors and all metabolic responses to glutamate were secondary to calcium entry. This review moves from those nostalgic times to the most recent advances in the physiology and pharmacology of mGlu receptors, and highlights the role of individual mGlu receptor subtypes in the pathophysiology of human disorders. This article is part of a Special Issue entitled 'Trends in Neuropharmacology: In Memory of Erminio Costa'.",
keywords = "Clinical studies, Metabotropic glutamate receptors, mGlu receptor ligands, Receptor structure",
author = "F. Nicoletti and J. Bockaert and Collingridge, {G. L.} and Conn, {P. J.} and F. Ferraguti and Schoepp, {D. D.} and Wroblewski, {J. T.} and Pin, {J. P.}",
year = "2011",
month = "6",
doi = "10.1016/j.neuropharm.2010.10.022",
language = "English",
volume = "60",
pages = "1017--1041",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",
number = "7-8",

}

TY - JOUR

T1 - Metabotropic glutamate receptors

T2 - From the workbench to the bedside

AU - Nicoletti, F.

AU - Bockaert, J.

AU - Collingridge, G. L.

AU - Conn, P. J.

AU - Ferraguti, F.

AU - Schoepp, D. D.

AU - Wroblewski, J. T.

AU - Pin, J. P.

PY - 2011/6

Y1 - 2011/6

N2 - Metabotropic glutamate (mGlu) receptors were discovered in the mid 1980s and originally described as glutamate receptors coupled to polyphosphoinositide hydrolysis. Almost 6500 articles have been published since then, and subtype-selective mGlu receptor ligands are now under clinical development for the treatment of a variety of disorders such as Fragile-X syndrome, schizophrenia, Parkinson's disease and l-DOPA-induced dyskinesias, generalized anxiety disorder, chronic pain, and gastroesophageal reflux disorder. Prof. Erminio Costa was linked to the early times of the mGlu receptor history, when a few research groups challenged the general belief that glutamate could only activate ionotropic receptors and all metabolic responses to glutamate were secondary to calcium entry. This review moves from those nostalgic times to the most recent advances in the physiology and pharmacology of mGlu receptors, and highlights the role of individual mGlu receptor subtypes in the pathophysiology of human disorders. This article is part of a Special Issue entitled 'Trends in Neuropharmacology: In Memory of Erminio Costa'.

AB - Metabotropic glutamate (mGlu) receptors were discovered in the mid 1980s and originally described as glutamate receptors coupled to polyphosphoinositide hydrolysis. Almost 6500 articles have been published since then, and subtype-selective mGlu receptor ligands are now under clinical development for the treatment of a variety of disorders such as Fragile-X syndrome, schizophrenia, Parkinson's disease and l-DOPA-induced dyskinesias, generalized anxiety disorder, chronic pain, and gastroesophageal reflux disorder. Prof. Erminio Costa was linked to the early times of the mGlu receptor history, when a few research groups challenged the general belief that glutamate could only activate ionotropic receptors and all metabolic responses to glutamate were secondary to calcium entry. This review moves from those nostalgic times to the most recent advances in the physiology and pharmacology of mGlu receptors, and highlights the role of individual mGlu receptor subtypes in the pathophysiology of human disorders. This article is part of a Special Issue entitled 'Trends in Neuropharmacology: In Memory of Erminio Costa'.

KW - Clinical studies

KW - Metabotropic glutamate receptors

KW - mGlu receptor ligands

KW - Receptor structure

UR - http://www.scopus.com/inward/record.url?scp=79954614494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954614494&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2010.10.022

DO - 10.1016/j.neuropharm.2010.10.022

M3 - Article

VL - 60

SP - 1017

EP - 1041

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - 7-8

ER -